North Star Holdings announced today that it has completed its first physical inspection with the U.S. Drug Enforcement Administration (DEA). The company, via its affiliates, recently submitted seven applications for cultivation of research cannabis with the DEA to offer pharmaceutical grade cannabis grown in multiple locations.
North Star is working to be the leader in pharmaceutical grade cannabis production with facilities encompassing more than 140 acres of outdoor cultivation and more than 500,000 square feet of indoor and greenhouse cannabis cultivation.
"The company believes these applications will position North Star as one of the largest companies in terms of square footage and number of licenses submitted by a single operator for cannabis research in the United States," says John Kaweske, CEO of North Star. "Our intended clients are universities, pharmaceutical and biotechnology companies."
North Star plans to offer researchers various cannabis genetic varieties to unlock new drug development for future FDA-approved treatments.
The University of Mississippi is the only DEA-licensed cannabis cultivator for research purposes in the United States.
North Star is hopeful that 2021 marks a new era of private entities and federal agencies working in cooperation to conduct cannabis research to help create new therapeutics.
The company and its affiliates own and operate multiple medical and retail marijuana centers, cultivation facilities and extraction labs under the brands Tweedleaf, Xleaf and Leaf Labs.